ヘパリン市場レポート：製品、由来、投与方法、用途、エンドユーザー、流通チャネル、地域別、2024-2032

世界のヘパリン市場規模は2023年に73億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて2.2%の成長率（CAGR）を示し、市場は2032年までに89億米ドルに達すると予測しています。心血管疾患に対する効果的な治療オプションに対するニーズの高まり、慢性疾患の大幅な増加、抗凝固療法を必要とする手術や侵襲的手技の増加、ドラッグデリバリーシステムにおける継続的な技術進歩などが、市場を牽引する要因の一例です。

ヘパリン（C12H19NO20S3）は広く使用されている抗凝固剤で、血液凝固を阻害する物質であり、様々な医療用途に不可欠です。動物組織を原料とするこの薬は、静脈、動脈、肺の血栓を防ぐために患者に投与されます。硫酸化多糖類を主成分とするヘパリンの特性には、作用発現の速さ、凝固酵素を不活性化するアンチトロンビンIIIと複合体を形成する能力などがあります。手術中、透析中、深部静脈血栓症や肺塞栓症の治療など、さまざまな医療場面で使用されています。ヘパリンは、身体の自然な抗凝固反応を高め、血栓を分解し、新たな血栓の形成を防ぐことによって作用します。

世界市場は主に、心血管疾患に対する効果的な治療オプションに対するニーズの高まりによって牽引されています。これに伴い、多様で手頃な価格のヘパリン製剤が広く利用できるようになったことも、市場に弾みをつけています。さらに、血液凝固障害に罹患しやすい高齢化人口の大幅な増加が、市場の重要な成長促進要因として作用しています。これに加えて、抗凝固療法を必要とする手術や侵襲的処置の増加が、製品需要の増加をもたらしています。さらに、血液関連疾患の適切な管理を必要とする組織化されたヘルスケアシステムの導入も市場を牽引しています。これとは別に、凝固障害につながる可能性のある生活習慣病の蔓延が市場を後押ししています。その他、急速な都市化と現代的なライフスタイル、より積極的な健康管理への文化的シフト、ヘルスケアプロバイダー、製薬会社、研究機関の広範な協力関係なども、市場に貢献している要因の一部です。

ヘパリン市場の動向と促進要因：

慢性疾患の大幅な増加

心臓病、がん、糖尿病などの慢性疾患の世界の増加により、抗凝固剤、特にヘパリンの使用が注目されています。これらの慢性疾患はしばしば血栓や血栓症のような二次的合併症を引き起こし、これらの致命的な事態を管理・予防するために抗凝固薬の投与が必要となります。ライフスタイルの進化に伴い、座りっぱなしの習慣、食生活の乱れ、その他の要因がこれらの慢性疾患の増加に寄与しているため、効果的な血栓管理治療に対する需要が高まっています。さらに、ヘルスケア開業医や医療機関は、リスクのある患者への使用を含む予防措置を推進しています。このように、ますます蔓延する疾患群による合併症の管理に抗凝固剤を幅広く応用することが、市場拡大の礎となっており、ヘルスケアにおける現在の慣行と将来の動向の両方を形成しています。

ドラッグデリバリーシステムの絶え間ない技術進歩

技術革新は市場にとって極めて重要な要素となっています。輸液ポンプ、プレフィルドシリンジ、ターゲットデリバリーなどのドラッグデリバリーシステムの進歩により、抗凝固剤をより正確かつ効果的に投与できるようになりました。これらの技術革新は過剰投与や副作用のリスクを低減し、患者の安全性と快適性を高めます。さらに、医療技術の進化に伴い、デジタルモニタリングとヘパリン投与との統合により、患者の反応をリアルタイムでモニタリングできるようになり、個別化された治療計画とより高い治療効果が可能になります。この技術への継続的な研究と投資は、抗凝固薬の全体的な使用感を向上させるだけでなく、ヘルスケアプロバイダーと患者の間の信頼も醸成します。この面における技術と医療の融合は、市場をよりダイナミックで患者中心の方向へと導く大きな原動力となっています。

高まる規制当局の支援と承認

市場の拡大は、さまざまな政府機関、国際機関、ヘルスケア当局を含む規制状況に大きな影響を受けています。厳しい規制環境は、ヘパリン製品が品質、安全性、有効性の基準を満たしていることを保証します。この精査は研究開発段階から市販後調査に至るまで、あらゆる段階に及んでいます。新しいヘパリン製剤や申請に対する迅速な承認プロセスは、明確なガイドラインや支援政策と並んで、薬剤の入手と適切な使用を促進するのに役立っています。さらに、規制当局の支援は、研究に対する財政的なインセンティブ、政府と製薬会社の協力、血栓障害に関する国民の意識向上キャンペーンにまで及ぶことが多いです。安全性と技術革新のバランスを保つ環境を育成することで、規制当局の支援はヘパリン市場の力強い成長における重要な柱として機能し、信頼を育み、最良の治療が必要とする患者に確実に届くようにします。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査目的
• 利害関係者
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 世界のヘパリン市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場内訳：製品別
• 市場内訳：由来別
• 市場内訳：投与方法別
• 市場内訳：用途別
• 市場内訳：エンドユーザー別
• 市場内訳：流通チャネル別
• 市場内訳：地域別
• 市場予測

第6章 市場内訳：製品別

• 未分画ヘパリン
  • 市場動向
  • 市場予測
• 低分子ヘパリン（LMWH）
  • 市場動向
  • 市場予測
• 超低分子ヘパリン（ULMWH）
  • 市場動向
  • 市場予測

第7章 市場内訳：由来別

• ウシ
  • 市場動向
  • 市場予測
• ブタ
  • 市場動向
  • 市場予測

第8章 市場内訳：投与方法別

• 経口
  • 市場動向
  • 市場予測
• 非経口
  • 市場動向
  • 市場予測

第9章 市場内訳：用途別

• 心房細動・心筋梗塞
  • 市場動向
  • 市場予測
• 脳卒中
  • 市場動向
  • 市場予測
• 深部静脈血栓症（DVT）
  • 市場動向
  • 市場予測
• 肺塞栓症（PE）
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第10章 市場内訳：エンドユーザー別

• 病院
  • 市場動向
  • 市場予測
• 診療所
  • 市場動向
  • 市場予測
• 在宅ケア
  • 市場動向
  • 市場予測
• 外来手術センター
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第11章 市場内訳：流通チャネル別

• 病院薬局
  • 市場動向
  • 市場予測
• 小売薬局
  • 市場動向
  • 市場予測
• ドラッグストア
  • 市場動向
  • 市場予測
• オンラインストア
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第12章 市場内訳：地域別

• 欧州
  • 市場動向
  • 市場予測
• 北米
  • 市場動向
  • 市場予測
• アジア太平洋
  • 市場動向
  • 市場予測
• 中東・アフリカ地域
  • 市場動向
  • 市場予測
• ラテンアメリカ
  • 市場動向
  • 市場予測

第13章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第16章 価格分析

第17章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • GlaxoSmithKline Plc
  • Shenzhen Hepalink Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Holdings
  • Baxter International Inc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Sandoz International GmbH
  • Opocrin S.p.A.
  • Sichuan Deebio Pharmaceutical Co., Ltd.
  • Dongying Tiandong Pharmaceutical Co., Ltd.

List of Figures

• Figure 1: Global: Heparin Market: Major Drivers and Challenges
• Figure 2: Global: Heparin Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Heparin Market: Breakup by Product (in %), 2023
• Figure 4: Global: Heparin Market: Breakup by Source (in %), 2023
• Figure 5: Global: Heparin Market: Breakup by Mode of Administration (in %), 2023
• Figure 6: Global: Heparin Market: Breakup by Application (in %), 2023
• Figure 7: Global: Heparin Market: Breakup by End-User (in %), 2023
• Figure 8: Global: Heparin Market: Breakup by Distribution Channel (in %), 2023
• Figure 9: Global: Heparin Market: Breakup by Region (in %), 2023
• Figure 10: Global: Heparin Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 11: Global: Heparin Industry: SWOT Analysis
• Figure 12: Global: Heparin Industry: Value Chain Analysis
• Figure 13: Global: Heparin Industry: Porter's Five Forces Analysis
• Figure 14: Global: Heparin (Unfractionated) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Heparin (Unfractionated) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Heparin (Low Molecular Weight) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Heparin (Low Molecular Weight) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Heparin (Ultra-Low Molecular Weight) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Heparin (Ultra-Low Molecular Weight) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Heparin (Bovine) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Heparin (Bovine) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Heparin (Porcine) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Heparin (Porcine) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Heparin (Oral) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Heparin (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Heparin (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Heparin (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Heparin (Atrial Fibrillation & Heart Attack) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Heparin (Atrial Fibrillation & Heart Attack) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Heparin (Stroke) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Heparin (Stroke) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Global: Heparin (Deep Vein Thrombosis) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Global: Heparin (Deep Vein Thrombosis) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Global: Heparin (Pulmonary Embolism) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Global: Heparin (Pulmonary Embolism) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Global: Heparin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Global: Heparin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Global: Heparin (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Global: Heparin (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Global: Heparin (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Global: Heparin (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: Global: Heparin (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: Global: Heparin (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Global: Heparin (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Global: Heparin (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Global: Heparin (Other End-Users) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Global: Heparin (Other End-Users) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Global: Heparin Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
• Figure 49: Global: Heparin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
• Figure 50: Global: Heparin Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
• Figure 51: Global: Heparin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
• Figure 52: Global: Heparin Market: Sales through Drug Stores (in Million US$), 2018 & 2023
• Figure 53: Global: Heparin Market Forecast: Sales through Drug Stores (in Million US$), 2024-2032
• Figure 54: Global: Heparin Market: Sales through Online Stores (in Million US$), 2018 & 2023
• Figure 55: Global: Heparin Market Forecast: Sales through Online Stores (in Million US$), 2024-2032
• Figure 56: Global: Heparin Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
• Figure 57: Global: Heparin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
• Figure 58: Europe: Heparin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: Europe: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: North America: Heparin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: North America: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Asia Pacific: Heparin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Asia Pacific: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: Middle East and Africa: Heparin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: Middle East and Africa: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Latin America: Heparin Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: Latin America: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

• Table 1: Global: Heparin Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Heparin Market Forecast: Breakup by Product (in Million US$), 2024-2032
• Table 3: Global: Heparin Market Forecast: Breakup by Source (in Million US$), 2024-2032
• Table 4: Global: Heparin Market Forecast: Breakup by Mode of Administration (in Million US$), 2024-2032
• Table 5: Global: Heparin Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 6: Global: Heparin Market Forecast: Breakup by End-User (in Million US$), 2024-2032
• Table 7: Global: Heparin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 8: Global: Heparin Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 9: Global: Heparin Market Structure
• Table 10: Global: Heparin Market: Key Players

The global heparin market size reached US$ 7.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.9 Billion by 2032, exhibiting a growth rate (CAGR) of 2.2% during 2024-2032. The increasing need for effective treatment options for cardiovascular diseases, considerable rise in the number of chronic conditions, the growing number of surgeries and invasive procedures requiring anticoagulation therapy, and continual technological advancements in drug delivery systems represent some of the factors that are propelling the market.

Heparin (C12H19NO20S3) is a widely used anticoagulant, a substance that inhibits blood clotting, making it essential in various medical applications. Sourced from animal tissues, this medication is administered to patients to prevent blood clots in veins, arteries, and lungs. Comprising mainly of sulfated polysaccharides, the properties of heparin include a rapid onset of action and the ability to form a complex with antithrombin III, which inactivates clotting enzymes. It's used in various medical situations such as during surgeries, dialysis, and in the treatment of deep vein thrombosis and pulmonary embolisms. Heparin works by enhancing the body's natural anticoagulant response, breaking down clots, and preventing the formation of new ones.

The global market is primarily driven by the increasing need for effective treatment options for cardiovascular diseases. In line with this, the widespread availability of varied and affordable heparin options is also providing an impetus to the market. Moreover, the considerable rise in the aging population, more susceptible to clotting disorders, is acting as a significant growth-inducing factor for the market. In addition to this, the growing number of surgeries and invasive procedures requiring anticoagulation therapy is resulting in higher product demand. The market is further driven by the implementation of organized healthcare systems that necessitate the proper management of blood-related conditions. Apart from this, the prevalence of lifestyle-related diseases that may lead to clotting disorders is propelling the market. Some of the other factors contributing to the market include rapid urbanization and modern lifestyles, the cultural shift towards more proactive health management, and extensive collaboration between healthcare providers, pharmaceutical companies, and research institutions.

Heparin Market Trends/Drivers:

Considerable rise in the number of chronic conditions

The global rise in chronic conditions such as heart disease, cancer, and diabetes has brought the use of anticoagulants, particularly heparin, into sharp focus. These chronic conditions often lead to secondary complications like blood clots and thrombosis, requiring the administration of anticoagulants to manage and prevent these potentially fatal occurrences. As lifestyles continue to evolve, sedentary habits, poor diet, and other factors are contributing to an increase in these chronic conditions, thereby pushing the demand for effective clot management treatments. Furthermore, healthcare practitioners and medical organizations are promoting preventive measures, including use in at-risk patients. This wide-ranging applications of this anticoagulant in managing complications from an increasingly prevalent group of diseases is serving as a cornerstone in the expansion of the market, shaping both current practices and future trends in healthcare.

Continual technological advancements in drug delivery systems

Technological innovation has become a pivotal factor in the market. The advancement in drug delivery systems, such as infusion pumps, prefilled syringes, and targeted delivery, ensures that the anticoagulant can be administered more accurately and effectively. These innovations reduce the risk of overdosage and side effects, thereby enhancing patient safety and comfort. Additionally, as medical technology evolves, the integration of digital monitoring with heparin delivery allows for real-time monitoring of patient response, enabling personalized treatment plans and greater therapeutic efficacy. The continuous research and investment in this technology not only improve the overall usage experience of anticoagulants but also foster trust among healthcare providers and patients. The convergence of technology and medicine in this aspect is a significant driving force, steering the market towards a more dynamic and patient-centric direction.

Growing regulatory support and approvals

The market expansion is significantly impacted by the regulatory landscape, encompassing various government bodies, international organizations, and healthcare authorities. The stringent regulatory environment ensures that heparin products meet quality, safety, and efficacy standards. This scrutiny extends to every stage, from the research and development phase to post-market surveillance. Rapid approval processes for new Heparin formulations and applications, alongside clear guidelines and supportive policies, help facilitate the drug's availability and proper usage. Furthermore, the regulatory support often extends to financial incentives for research, collaboration between governments and pharmaceutical companies, and public awareness campaigns about blood clot disorders. By cultivating an environment that balances safety with innovation, the regulatory support serves as a key pillar in the robust growth of the Heparin market, fostering trust, and ensuring that the best possible care reaches patients in need.

Heparin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global heparin market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on product, source, mode of administration, application, end-user and distribution channel.

Breakup by Product:

Unfractionated Heparin

Low Molecular Weight Heparin (LMWH)

Ultra-Low Molecular Weight Heparin (ULMWH)

Low molecular weight heparin (LMWH) represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). According to the report, low molecular weight heparin (LMWH) represented the largest segment.

The growing preference for low molecular weight heparin (LMWH) can be attributed to its enhanced bioavailability and prolonged action compared to the unfractionated variant. LMWH offers a more predictable dose-response relationship, reducing the need for frequent monitoring and dose adjustments. Its lower risk of causing heparin-induced thrombocytopenia (HIT) contributes to its favorability in both prophylactic and therapeutic settings. Additionally, LMWH's ease of subcutaneous administration and potential for outpatient care further promote its adoption, aligning with the trend towards patient-centric healthcare.

On the other hand, the unfractionated heparin and ultra-low molecular weight heparin (ULMWH) segments of the market are driven by several factors. These factors include their clinical efficacy in preventing and treating thrombotic conditions, their diverse applications in addressing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, and the influence of physician preferences based on patient profiles and medical history.

Breakup by Source:

Bovine

Porcine

Porcine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the source. This includes bovine and porcine. According to the report, porcine represented the largest segment.

The utilization of porcine mucosal tissues as the primary product source is driven by the high concentration of precursors in these tissues. Porcine source remains integral to the heparin production process due to its reliability, scalability, and cost-effectiveness. However, the industry's ongoing exploration of alternative sources, driven by concerns over availability and ethical considerations, underscores the importance of diversifying raw material options to ensure a stable supply chain for this critical anticoagulant.

On the other hand, the use of heparin sourced from bovine origins has been historically prominent in medical applications due to its availability and established track record. Also, continual advances in purification processes have addressed concerns related to potential contaminants and allergenic reactions associated with bovine-sourced anticoagulants, which is impelling the segment.

Breakup by Mode of Administration:

Oral

Parenteral

Oral represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the mode of administration. This includes oral and parenteral. According to the report, oral represented the largest segment.

The development of oral formulations for anticoagulants marks a significant advancement in patient care. The shift from injectable to oral administration stems from the desire to enhance patient compliance, reduce the burden of injections, and facilitate long-term therapy. However, the challenge lies in achieving consistent bioavailability and maintaining predictable anticoagulation effects with oral formulations. Extensive research and clinical trials are being conducted to refine oral anticoagulant drugs, aiming to strike a balance between efficacy, safety, and convenience.

On the other hand, the parenteral mode of administration, involving injections, offers immediate effects that are particularly suitable for acute situations such as stroke and thrombotic events. This mode of administration ensures predictable dosing, which enhances patient safety and treatment efficacy.

Breakup by Application:

Atrial Fibrillation & Heart Attack

Stroke

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Others

Atrial fibrillation and heart attacks account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. According to the report, atrial fibrillation and heart attacks represented the largest segment.

Atrial fibrillation and heart attacks are pivotal drivers of the demand for various anticoagulants. The increased incidence of these conditions underscores the critical role of timely and effective anticoagulation in preventing thromboembolic events. Atrial fibrillation, characterized by irregular heart rhythms, necessitates ongoing anticoagulant therapy to prevent blood clot formation and potential stroke. Meanwhile, in the context of heart attacks, the product's role as an adjunctive therapy complements other interventions to prevent further clotting and optimize patient outcomes.

On the other hand, the rising prevalence of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) drives the demand for effective anticoagulation therapies. The aging global population contributes to a higher incidence of these conditions, emphasizing the need for suitable treatment options.

Breakup by End-User:

Hospitals

Clinics

Homecare Settings

Ambulatory Surgical Centers

Others

Hospitals represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes hospitals, clinics, homecare settings, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.

Hospitals serve as central hubs for patient care, where the use of heparin spans from surgical procedures to the treatment of thrombotic events for preventing blood clot formation. Hospitals' high patient throughput and critical nature of care emphasize the need for accessible and effective anticoagulation options. As healthcare facilities continue to evolve, optimizing product utilization and management within hospital protocols contributes to patient safety and overall quality of care.

On the other hand, the growing product applications across clinics, homecare settings, and ambulatory surgical centers reflects its versatility in catering to different patient care environments. This is especially convenient for patients, as it allows effective treatment in home-based or ambulatory settings.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Stores

Others

Hospital pharmacies account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, drug stores, online stores, and others. According to the report, hospital pharmacies represented the largest segment.

Hospital pharmacies play a pivotal role in the anticoagulant distribution and management within healthcare institutions. Their efficient procurement, storage, and dispensing of pharmaceuticals impact the product availability for clinicians. Additionally, hospital pharmacies facilitate communication between healthcare providers and manufacturers, ensuring timely restocking and adherence to quality standards. An effectively managed distribution channel contributes to seamless patient care and supports hospital staff in delivering appropriate therapies in a timely manner.

On the other hand, the easy product accessibility in retail pharmacies, drug stores, and online stores ensures wider patient access to necessary anticoagulant medications. This availability caters to diverse consumer preferences, allowing some patients to conveniently obtain anticoagulants from their preferred retail or online sources.

Breakup by Region:

Europe

North America

Asia Pacific

Middle East and Africa

Latin America

North America exhibits a clear dominance, accounting for the largest heparin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market in the North America region is propelled by the region's high incidence of chronic diseases, notably cardiovascular disorders, deep vein thrombosis, and pulmonary embolism, fuels the demand for heparin as a vital anticoagulant and thromboprophylactic agent.

This demand is further magnified by the increasing proportion of the aging population, a demographic more prone to conditions necessitating anticoagulant treatment. The region's advanced healthcare infrastructure, coupled with the burgeoning number of surgical procedures, including cardiovascular surgeries and orthopedic interventions, fosters a significant need for heparin-based products to mitigate blood clot formation risks.

Improved awareness of thrombotic disorders and enhanced diagnostic techniques contribute to early detection and treatment, amplifying the necessity for product interventions. The stringent regulatory landscape in North America ensures the secure and effective utilization of anticoagulant drugs, including heparin, while ongoing research, collaborative endeavors, and innovations in the field continually refine product efficacy and safety profile. In summation, a dynamic interplay of demographic trends, healthcare infrastructure, medical awareness, regulatory standards, and research advancements collectively stimulate the rising demand for anticoagulant products across various medical domains.

Competitive Landscape:

The leading market players are investing significantly in R&D to develop improved formulations and delivery methods, enhancing the effectiveness and safety of heparin products. These efforts aim to address medical needs more efficiently and reduce potential side effects. To tap into new markets and diversify revenue streams, major manufacturers are expanding their geographic presence by establishing distribution networks, manufacturing facilities, and sales operations in emerging markets. Additionally, they are investing in advanced quality control measures, adherence to Good Manufacturing Practices (GMP), and transparency in their supply chains to maintain customer trust and regulatory approval. The key players are also forming strategic partnerships with research institutions, healthcare providers, and pharmaceutical companies to collectively advance heparin-based treatments.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

GlaxoSmithKline Plc

Shenzhen Hepalink Pharmaceutical Co., Ltd

Pfizer Inc.

LEO Pharma A/S

Sanofi S.A.

Dr. Reddy's Laboratories Ltd.

Teva Pharmaceutical Industries Ltd.

Aspen Holdings

Baxter International Inc.

Hebei Changshan Biochemical Pharmaceutical Co. Ltd.

Sandoz International GmbH

Opocrin S.p.A.

Sichuan Deebio Pharmaceutical Co., Ltd.

Dongying Tiandong Pharmaceutical Co. Ltd.

Recent Developments:

In June 2023, GlaxoSmithKline Plc completed the acquisition of BELLUS, a biopharmaceutical company focusing on refractory chronic cough (RCC) treatment, by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.

In June 2023, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.

In May 2021, Dr. Reddy's Laboratories Ltd. along with its subsidiaries announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

Key Questions Answered in This Report

• 1. How big is the global heparin market?
• 2. What is the expected growth rate of the global heparin market during 2024-2032?
• 3. What are the key factors driving the global heparin market?
• 4. What has been the impact of COVID-19 on the global heparin market?
• 5. What is the breakup of the global heparin market based on the product?
• 6. What is the breakup of the global heparin market based on the source?
• 7. What is the breakup of the global heparin market based on the mode of administration?
• 8. What is the breakup of the global heparin market based on the application?
• 9. What is the breakup of the global heparin market based on the end-user?
• 10. What is the breakup of the global heparin market based on the distribution channel?
• 11. What are the key regions in the global heparin market?
• 12. Who are the key players/companies in the global heparin market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Heparin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Product
• 5.5 Market Breakup by Source
• 5.6 Market Breakup by Mode of Administration
• 5.7 Market Breakup by Application
• 5.8 Market Breakup by End-User
• 5.9 Market Breakup by Distribution Channel
• 5.10 Market Breakup by Region
• 5.11 Market Forecast

6 Market Breakup by Product

• 6.1 Unfractionated Heparin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Low Molecular Weight Heparin (LMWH)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Source

• 7.1 Bovine
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Porcine
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Mode of Administration

• 8.1 Oral
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Parenteral
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Application

• 9.1 Atrial Fibrillation & Heart Attack
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Stroke
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Deep Vein Thrombosis (DVT)
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Pulmonary Embolism (PE)
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by End-User

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Homecare Settings
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Ambulatory Surgical Centers
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Others
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Market Breakup by Distribution Channel

• 11.1 Hospital Pharmacies
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Retail Pharmacies
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Drug Stores
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast
• 11.4 Online Stores
  • 11.4.1 Market Trends
  • 11.4.2 Market Forecast
• 11.5 Others
  • 11.5.1 Market Trends
  • 11.5.2 Market Forecast

12 Market Breakup by Region

• 12.1 Europe
  • 12.1.1 Market Trends
  • 12.1.2 Market Forecast
• 12.2 North America
  • 12.2.1 Market Trends
  • 12.2.2 Market Forecast
• 12.3 Asia Pacific
  • 12.3.1 Market Trends
  • 12.3.2 Market Forecast
• 12.4 Middle East and Africa
  • 12.4.1 Market Trends
  • 12.4.2 Market Forecast
• 12.5 Latin America
  • 12.5.1 Market Trends
  • 12.5.2 Market Forecast

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 GlaxoSmithKline Plc
  • 17.3.2 Shenzhen Hepalink Pharmaceutical Co., Ltd
  • 17.3.3 Pfizer Inc.
  • 17.3.4 LEO Pharma A/S
  • 17.3.5 Sanofi S.A.
  • 17.3.6 Dr. Reddy's Laboratories Ltd.
  • 17.3.7 Teva Pharmaceutical Industries Ltd.
  • 17.3.8 Aspen Holdings
  • 17.3.9 Baxter International Inc.
  • 17.3.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • 17.3.11 Sandoz International GmbH
  • 17.3.12 Opocrin S.p.A.
  • 17.3.13 Sichuan Deebio Pharmaceutical Co., Ltd.
  • 17.3.14 Dongying Tiandong Pharmaceutical Co., Ltd.